Human VEGF-165 Recombinant Protein #48143
Product Information
Storage
Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC.
Product Description
| MW (kDa) | 19.3 |
| Purity | A greater than or equal to 95% purity was determined by SDS-PAGE. |
| Endotoxin | Endotoxin levels are less than or equal to 1 EU / 1 μg hVEGF-165. |
| Activity | The bioactivity of recombinant hVEGF-165 was determined in a HUVEC cell proliferation assay. The ED50 of each lot is less than or equal to 10 ng/ml. |
Source / Purification
Recombinant human VEGF-165 was expressed in E. coli and is supplied in a lyophilized form.
Background
VEGF-165 is the most abundant splice variant of VEGF-A (1,2). VEGF-165 is produced by a number of cells including endothelial cells, macrophages, and T cells. VEGF-165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration, and vascular permeability (1). VEGF gene expression is induced by hypoxia, inflammatory cytokines, and oncogenes (1,2). VEGF-165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (2,3). VEGF-165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 (1). VEGF-165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 (1-3) that function to enhance VEGFR2 signaling (1). Binding of VEGF-165 to VEGFR1 and VEGFR2 leads to activation of PI3K/Akt, p38 MAPK, FAK and paxillin (1). VEGF plays a key role in tumor angiogenesis in many cancers (2).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.